Introduction
Neuroblastoma (NB) is an embryonic tumor derived from the neural crest cells. It is the most common solid tumor in infants and children, and it accounts for approximately 15% of deaths due to pediatric tumors [1, 2] . NB is characterized by a large clinical heterogeneity.
Indeed, these tumors may regress completely or differentiate into a benign ganglioneuroblastoma without treatment while metastatic NB in children older than 18 months at diagnosis are lethal for most patients despite aggressive multimodal therapy [3] .
Several critical genetic aberrations, such as deletions 1p, 3p and 11q or gains 1q, 2p and 17q, are identified in NB but only few established molecular markers are associated with outcome. The most important is the amplification of the MYCN locus that is found in about 25% of NB, and is strongly related to poor clinical outcome [1, 2] . The involvement of MYCN in NB tumorigenesis was demonstrated in transgenic mice overexpressing MYCN in neural crest cells [4] . High expression of the transcription factor MYCN disrupts the cell-cycle exit and terminal differentiation that occurs during normal neuroblast development [5, 6] . MYCN also plays an important role in cell invasion by directly or indirectly modulating specific target genes involved in cell adhesion, motility and matrix degradation [7] .
Another oncogene found in NB is the anaplastic lymphoma kinase (ALK). This tyrosine kinase receptor collaborates with MYCN for the development of most aggressive NB [8] . The F1174L ALK mutation is associated preferentially with MYCN amplification in NB and induces constitutive activation of the PI3K/AKT pathway [9, 10] . This constitutive activation leads to oncogenic stabilization of MYCN protein [11] . Poorly differentiated NB with high expression of MYCN and the F1174L ALK mutation define a subset of patients with high-risk NB [9, 12] .
Treating patients with high-risk NB is a challenge because about one-third of these patients do not respond completely to induction therapy [13, 14] . New therapies inducing differentiation of NB cells and inhibiting specific signaling pathways, angiogenesis and ALK and MYCN expression are in development [7, 15, 16] .
The vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACAP) are 2 related neuropeptides that share common receptors, named VPAC1 and VPAC2 [17] . These two receptors bind VIP and PACAP equally and activate mainly the protein kinase A (PKA) and protein kinase C (PKC) signaling pathways, which induce regulation of gene expression [18] . VIP and PACAP are involved in the development of the nervous system. VIP regulates the proliferation and the differentiation of neuronal precursors in vitro and in vivo, and is involved in the growth, differentiation and maintenance of neurons [19] [20] [21] . VIP can also regulate proliferation, differentiation and migration of various tumor cells [21, 22] . In NB cell lines, this neuropeptide induces both inhibition of growth and morphological differentiation [23] . The rate of VIP increases with the degree of differentiation of NB and is associated with a good prognosis [24] [25] [26] . Our group demonstrated that VIP induces morphologic differentiation (neuritogenesis) and reduces MYCN expression in the high-risk NB IMR-32 cells with MYCN amplification [27] . Then VIP can regulate several processes that are the targets of new therapeutic strategies for high-risk NB. VIP can also up-or down-regulate invasion of different cancer cells depending of their tissue of origin [28] [29] [30] [31] [32] . However, its effect on NB cell invasion is unknown.
In the present study, we analyzed the effect of VIP on different molecular and cellular processes, i.e. neuritogenesis, MYCN expression, AKT activity and cell invasion, in high-risk NB cell lines with MYCN amplification, one also presenting the F1174L ALK mutation.
Furthermore, the activity of stable peptidic analogs of PACAP developed for therapeutic use [33] [34] [35] , was tested.
Materials and methods

Cell culture
Kelly and IMR-32 NB MYCN-amplified cells were routinely seeded at a density of 10 6 cells/25 cm 2 flask in RPMI 1640 medium or DMEM medium 4.5g/L glucose, respectively, with GlutaMAX™ (Gibco) supplemented with 10% fetal calf serum (FCS) and 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen). These cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. SK-N-DZ cells were routinely seeded at a density of 10 6 cells/25 cm 2 flask in DMEM medium with GlutaMAX supplemented with 10% fetal calf serum (FCS) and 1% non essential amino acids (Sigma). SK-N-DZ cells were incubated at 37°C in a humidified atmosphere of 10% CO 2 in air. For all cell lines, medium was changed every 3 days. Passages were performed once per week using 1X Trypsin/EDTA (Invitrogen).
Peptides
The VIP, PACAP-38, PACAP-27 and Secretin were from Neosystem (Strasbourg, France) while analogs were synthesis as previously described. Neuropeptides and analogs were diluted to a concentration of 10 -4 M in pure water or DMEM.
Treatments
Kelly, IMR-32 cells were seeded at a density of 2x10 6 and SK-N-DZ cells at 0.5x10 6 cells/25 cm 2 flask in the media mentioned above except that they were supplemented with 5% FCS. 
Micrographs of cells
Video images of cells were captured using a digital camera connected to a phase-contrast Olympus microscope. The quantification of the number of cells with neurites and the measure of neurite length were performed using ImageJ software.
Western immunoblot analysis
After treatment, cells were recovered with versene, and cold PBS was added. Cells were 
Real-time RT-PCR and quantification
The protocol of RT-qPCR was carried out with the LightCycler System (Roche Molecular Biochemicals) by using the « SYBR Premix Ex Taq kit» (Takara) as previously described [36] . GAPDH mRNA levels were used to normalize the mRNA levels between samples.
MYCN primers used were as followed:
CGACCACAAGGCCCTCAGT, MYCN reverse: TGACCACGTCGATTTCTTCCT.
GAPDH primers used were as followed:
GAAGGTGAAGGTCGGAGTCA, GAPDH reverse: GACAAGCTTCCCGTTCTCAG. The cycle program was: 5 sec at 95˚C, 5 sec at 60˚C and 10 sec at 72˚C.
Invasion
Invasion assays were carried out by using 24-well culture plates (BD Biosciences) using
Transwell polycarbonate membrane filter inserts (8-µm pore size, BD Biosciences) coated with Matrigel (BD Biosciences) diluted at 1/80. Cells were collected using Versene solution.
After centrifugation, cells were resuspended in medium containing 5% FBS, incubated for 30 
Statistical analyses
Statistical analyses were performed using the software GraphPad Prism.
Results
I-VIP induces neuritogenesis in neuroblastoma cells
VIP is able to induce neurite outgrowth in the MYCN-amplified IMR-32 cell line [27, 37, 38] . In order to determine whether this differentiation process was found in other cell 
II-VIP decreases MYCN expression in Kelly cells
We previously observed that VIP decreased the expression of MYCN at the mRNA and protein levels in IMR-32 cell line [27] . Here, the effect of VIP on MYCN expression was 
IV-VIP inhibits Kelly and IMR-32 cell invasion
MYCN plays an important role in NB invasion [7] . To determine whether VIP can also 
V-VIP-induced inhibition of AKT activity is PKA-dependent
The PI3K/AKT signaling pathway is known to stabilize MYCN protein [16] . Kelly cells present the F1174L ALK mutation that induces the constitutive activation of AKT, among others. We verified that AKT stabilizes MYCN protein in Kelly cells. In the presence of the AKT inhibitor (AI) at 10 µM for 6 h, MYCN protein decreased ( Figure 5A ) confirming that AKT stabilizes MYCN protein in these cells. We next wondered whether VIP acts on AKT activity. Phosphorylation of AKT at serine 473 is necessary for its kinase activity [39] . The data indicated that VIP decreased phosphorylation at serine 473 (P-AKT) after 3 and 6 h of treatment with VIP, in correlation with reduced MYCN expression. This reduction of P-AKT by VIP was PKA-dependent, as demonstrated when Kelly cells were pre-incubated with H-89 and next treated with VIP for 6h ( Figure 5C ). Indeed, in presence of H-89 at 10 µM, VIP had no effect on P-AKT, indicating that VIP inhibits AKT activity via PKA, in parallel to its reduction in MYCN expression.
VIEffects of PACAP analogs on AKT activity
VIP activity is mediated by the two receptors VPAC1 and VPAC2 that also bind the related peptide PACAP with equal affinity. PACAP is also the specific ligand of the receptor PAC1 [17] . 
Discussion
New therapies are needed to improve the treatment of patients with high-risk NB.
Knowledge of the molecular and cellular characteristics of these high-risk NB allows to consider the development of treatments able to induce NB differentiation and inhibition of signaling pathways, angiogenesis and the expression of the oncogenes ALK and MYCN [7] .
The transcription factor MYCN regulates many processes in NB cells, notably differentiation, metastasis, angiogenesis and then constitutes a major therapeutic target. This therapeutic relevance was demonstrated in a mouse model of NB that overexpresses MYCN in cells derived from neural crest. In these mice, the administration of antisense oligonucleotides inhibiting MYCN expression reduces the tumor incidence and tumor mass [40] . Here, we Metastases are the main cause of death of NB patients [43] . MYCN plays an important role in NB invasion. Indeed, this transcriptional factor directly or indirectly can down-regulate integrin expression, up-regulate transcription of focal adhesion kinase (FAK), induce MMP activity and inhibit E-cadherin expression [7] . These modulations increase migration and invasion of NB cells. Here, we report that VIP reduces in vitro invasion in both Kelly and IMR-32 MYCN-amplified cells. In our experiments, Kelly cells were about 9-fold more invasive than IMR-32 cells. This is in agreement with the observation that invasion capacity of NB cells correlates with MYCN levels [7] . Indeed, Kelly and IMR-32 cells possess about 100-120 and 15 copies of MYCN per haploide genome, respectively [43, 44] . The effect of VIP on invasion of these two cell lines was about 50-60%, even in the highly invasive and highly ALK is another therapeutic target considered for the treatment of NB [16] . Mutations of this receptor tyrosine kinase collaborate with MYCN in NB pathogenesis [8, 10] . These mutations lead to constitutive activation of AKT signaling, a pathway known to inhibit MYCN proteasomal degradation [45] . In our study, the inhibition of AKT activity induced by VIP could be responsible for the post-translational down-regulation of MYCN expression observed in VIP-treated Kelly cells.
MYCN-amplified
Numerous ALK mutations have been identified in NB cells [9] . The ALK mutations F1178L and R1279Q were recently shown to increase VIP expression in NB tumors from mice with one of these ALK mutations and overexpressing MYCN [46] . Whether the F1174L ALK mutation could up-regulate VIP expression in Kelly cells is unknown, but if this happens, then the endogenous VIP is not produced enough to prevent exogenous VIP to act on these cells.
PKA is often involved in the signaling triggered by VIP [18] . Our data indicate that the effect of VIP on neuritogenesis and MYCN expression in Kelly and IMR-32 cells, as well as on AKT activity in Kelly cells, is PKA-dependent. Thus PKA plays an important role in VIP signaling in NB cells, as we observed in glioblastoma cells (Bensalma et al., manuscript in preparation) that also derived from the nervous system.
Peptidic analogs of PACAP that are more resistant to peptidases and more selective for certain receptors were designed for therapy [33] [34] [35] . In the high-risk NB Kelly cells, the most effective of the five analogs tested is [Hyp 2 ]PACAP-27. Indeed, this analog is more potent than VIP on neuritogenesis, MYCN expression, AKT activity and cell invasion.
[Hyp 2 ]PACAP-27 corresponds to PACAP-27 in which serine at position 2 is replaced by hydroxyproline. This modification confers selectivity for PAC1/VPAC1 receptors because of a lower activation of VPAC2 receptors, as determined in transfected CHO cells expressing the human PAC1, VPAC1 or VPAC2 [35, 47] . This suggests that, in Kelly cells, the effect of VIP is mediated by the VPAC1 receptor which binds VIP and PACAP while PAC1 is a PACAPspecific receptor. However, further investigations are required to determine which receptor is involved, because VPAC1 mRNA is only weakly expressed in Kelly cells while VPAC2
mRNA is present in a large quantity (de Boisvilliers, unpublished data).
In the kinetic experiments with VIP and PACAP analogs (Figure 6 ), a biphasic effect on phospho-AKT is often observed with a decrease in P-AKT at 1-2 h and at 6 h but not at the intermediate time point (3 h ). This could be due to receptor desensitization, down-regulation or internalization as already described for VIP and PACAP receptors [48, 49] .
This study showed that VIP and PACAP analogs developed for therapy act on molecular and cellular processes that are of interest for treatment of high-risk NB. So far, small molecules directly inhibiting MYCN have not yet been found, thus non-small molecules and indirect inhibitors are sought for therapy [7, 16] . Peptidic analogs able to induce a sustainable decrease in MYCN expression would be of interest not only for therapy of NB but also for other tumors such as neuroendocrine prostate cancer for which 40% present a MYCN amplification [50] . AKT analysis was performed as described in Figure 5 B. Top panels correspond to a representative experiment and bottom panels present cumulative data after quantification using densitometry. The histogram bars represent the mean ± SEM. The data were expressed as mean ± SEM from three independent experiments for VIP and PACAP-38, and from two independent experiments for analogs. The statistical test used was the Friedman test (*P < 0.05, **P < 0.01, ***P < 0.001). Each treatment was compared to control (t = 0 h). 
